Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 11, 2013
Predictors and dynamics of postpartum relapses in women with multiple sclerosisStella E Hughes, Tim Spelman, Orla M Gray, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 11, 2013
Predictors and dynamics of postpartum relapses in women with multiple sclerosisStella E Hughes, Tim Spelman, Orla M Gray, et al.
Brain : a Journal of Neurology|July 13, 2016
Defining secondary progressive multiple sclerosisJohannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, et al.
Annals of Neurology|October 7, 2014
Seasonal variation of relapse rate in multiple sclerosis is latitude dependentTim Spelman, Orla Gray, Maria Trojano, et al.
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
Brain : a Journal of Neurology|September 18, 2020
Delay from treatment start to full effect of immunotherapies for multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2020
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosisMinh Le, Charles Malpas, Sifat Sharmin, et al.
Pageof 12